Categories: HealthcareNews

Nihon Kohden Introduces First-Ever ATO-Certified Ventilators

IRVINE, Calif.–(BUSINESS WIRE)–#RespiratoryCare–Nihon Kohden, a global leader in medical technology, today announced the introduction of the industry’s first ventilators to receive Authority to Operate (ATO) certification under the Department of Defense’s (DoD) Risk Management Framework (RMF) eMASS #3389. This rigorous cybersecurity certification ensures Nihon Kohden’s ventilators meet the highest standards for data protection and operational security in healthcare settings.


“Our ATO-certified ventilators represent a new standard in medical device security,” said Roy Sakai, President of Nihon Kohden America. “This certification shows our commitment to protecting patient data and supporting healthcare providers in today’s digital world.”

Benefits of ATO-certified ventilators

  • Stronger patient data protection
  • Faster setup and installation
  • Lower risk of cyber attacks

Nihon Kohden’s commitment to maintaining this certification ensures its ventilators remain at the forefront of cybersecurity protection.

For more information about Nihon Kohden’s ATO-certified ventilators, please visit us.nihonkohden.com.

About Nihon Kohden

Founded in Japan in 1951, Nihon Kohden is a leading manufacturer, developer, and distributor of medical electronic equipment, with subsidiaries in the U.S., Europe, Asia, and Latin America. The company’s products are now used in more than 120 countries, and it is the largest supplier of electroencephalography products worldwide. A pioneer in transformational healthcare technology, Nihon Kohden has envisioned, designed, and produced revolutionary devices, such as pulse oximeters, arrhythmia analysis, low- invasive blood volume monitoring, and wireless patient monitoring.

Contacts

Beth Abbott

Senior Manager – Marketing Brand & Omnichannel

beth_abbott@nihonkohden.com

Staff

Recent Posts

AMEEREX Signs MOU to Acquire 45.6 million-Ounce Silver-Gold Project in Nevada, Expanding Its North American Precious-Metals Portfolio

ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…

34 minutes ago

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…

7 hours ago